Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • inflammatory

    - PMLiVE

    Abivax shares positive late-stage results for obefazimod in ulcerative colitis

    Inflammatory bowel disease affects nearly one in every 100 people in the US

    - PMLiVE

    Bristol Myers Squibb’s Reblozyl receives EC approval in myelodysplastic syndromes

    The treatment is already approved in the EU to treat anaemia in adults with beta-thalassaemia

    - PMLiVE

    GSK’s Omjjara recommended by NICE to treat myelofibrosis patients with anaemia

    Myelofibrosis is estimated to affect over 1,900 people in England, Wales and Northern Ireland

    - PMLiVE

    GSK’s Omjjara approved by MHRA to treat myelofibrosis patients with anaemia

    The rare blood cancer affects approximately one in every 500,000 people worldwide

    - PMLiVE

    GSK’s Omjjara approved by EC to treat myelofibrosis patients with anaemia

    About 40% of myelofibrosis patients have moderate-to-severe anaemia at the time of diagnosis

    - PMLiVE

    GSK’s momelotinib recommended by CHMP to treat myelofibrosis patients with anaemia

    About 40% of patients have moderate-to-severe anaemia at the time of diagnosis

    - PMLiVE

    GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia

    Myelofibrosis is a rare blood cancer affecting approximately 25,000 patients in the US

    - PMLiVE

    GSK’s application for momelotinib in myelofibrosis with anaemia accepted by FDA

    40% of myelofibrosis patients are already anaemic at the time of diagnosis and nearly all patients are estimated to develop anaemia eventually

    - PMLiVE

    Dovetail wins Communiqué Agility and Flexibility award at Communiqué 2021

    This inaugural award was given to Dovetail amid fierce competition from four other agencies

    - PMLiVE

    Gut instincts lead Takeda to GI pipeline success

    Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy

    - PMLiVE

    Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year

    Late-stage candidate hit the mark in phase 3 study

    - PMLiVE

    Pfizer’s Xeljanz picks up a third indication in the US

    The JAK inhibitor can now treat patients with ulcerative colitis

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links